Eugene Washington - Johnson Johnson Independent Director
JNJ Stock | MXN 2,478 31.42 1.28% |
Director
Dr. A. Eugene Washington, M.D., M.Sc. is an Independent Director of the Company. He is currently Duke Universitys Chancellor for Health Affairs and the President and Chief Executive Officer of the Duke University Health System. Previously he was Vice Chancellor of Health Sciences, Dean of the David Geffen School of Medicine at UCLA Chief Executive Officer of the UCLA Health System and Distinguished Professor of Gynecology and Health Policy at UCLA. Prior to UCLA, he served as Executive Vice Chancellor and Provost at the University of California, San Francisco from 2004 to 2010. Dr. Washington cofounded UCSFs Medical Effectiveness Research Center for Diverse Populations in 1993 and served as Director until 2005. He was Chair of the Department of Obstetrics, Gynecology, and Reproductive Sciences at UCSF from 1996 to 2004. Dr. Washington also cofounded the UCSFStanford Evidencebased Practice Center and served as its first Director from 1997 to 2002. Prior to UCSF, Dr. Washington worked at the Centers for Disease Control and Prevention. Dr. Washington was elected to the National Academy of Sciences Institute of Medicine in 1997, where he served on its governing Council. He was founding Chair of the Board of Governors of the PatientCentered Outcomes Research Institute, served as a member of the Scientific Management Review Board for the NIH, and also served as Chair of the Board of Directors of both the California HealthCare Foundation and The California Wellness Foundation. Dr. Washington currently serves on the Boards of Directors of the Kaiser Foundation Hospitals and Kaiser Foundation Health Plan, Inc. since 2012.
Age | 67 |
Tenure | 12 years |
Phone | 732 524 0400 |
Web | https://www.jnj.com |
Johnson Johnson Management Efficiency
The company has return on total asset (ROA) of 0.0881 % which means that it generated a profit of $0.0881 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2414 %, meaning that it generated $0.2414 on every $100 dollars invested by stockholders. Johnson Johnson's management efficiency ratios could be used to measure how well Johnson Johnson manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | DIRECTOR Age | ||
Robert Coretz | Air Transport Services | 54 | |
Daniel Quintanilla | GMxico Transportes SAB | 43 | |
Arturo Ayub | GMxico Transportes SAB | 51 | |
John Teets | Air Transport Services | 45 | |
Laura Peterson | Air Transport Services | 58 | |
MaryAnn Wright | Micron Technology | 56 | |
Leo Mackay | Cognizant Technology Solutions | 56 | |
Michael PatsalosFox | Cognizant Technology Solutions | 65 | |
Warren East | Micron Technology | 52 | |
Maureen BreakironEvans | Cognizant Technology Solutions | 63 | |
Ivan Donaldson | Micron Technology | N/A | |
Betsy Atkins | Cognizant Technology Solutions | 63 | |
Lawrence Mondry | Micron Technology | 56 | |
Mark Heil | Micron Technology | 52 | |
Joseph Velli | Cognizant Technology Solutions | 60 | |
Ivanhoe Donaldson | Micron Technology | N/A | |
Roberto Seade | GMxico Transportes SAB | N/A | |
Robert Bailey | Micron Technology | 61 | |
Patrick Byrne | Micron Technology | 57 | |
Raymond Johns | Air Transport Services | 63 | |
Lynn Dugle | Micron Technology | 60 |
Management Performance
Return On Equity | 0.24 | |||
Return On Asset | 0.0881 |
Johnson Johnson Leadership Team
Elected by the shareholders, the Johnson Johnson's board of directors comprises two types of representatives: Johnson Johnson inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Johnson. The board's role is to monitor Johnson Johnson's management team and ensure that shareholders' interests are well served. Johnson Johnson's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Johnson Johnson's outside directors are responsible for providing unbiased perspectives on the board's policies.
A Washington, Independent Director | ||
Dirk Brinckman, Chief Officer | ||
Jennifer Doudna, Independent Director | ||
Alex Gorsky, Chairman, CEO, Chairman of Executive Committee and Chairman of Fin. Committee | ||
William Perez, Independent Director | ||
Michael Sneed, Executive Vice President - Global Corporate Affairs and Chief Communication Officer | ||
Marillyn Hewson, Independent Director | ||
Jorge Mesquita, Executive Vice President Worldwide Chairman - Consumer | ||
Mary Coleman, Independent Director | ||
Michael Ullmann, VP, General Counsel and Member of Executive Committee | ||
Joaquin Duato, Executive Vice President Worldwide Chairman - Pharmaceuticals | ||
Joseph CPA, Ex CFO | ||
Kathy Wengel, Executive Vice President Chief Global Supply Chain Officer | ||
Jennifer Taubert, Executive Vice President - Worldwide Chairman, Pharmaceuticals | ||
Mary Beckerle, Independent Director | ||
Sandra Peterson, Group Worldwide Chairman and Member of Executive Committee | ||
Scott Davis, Director | ||
Louise Mehrotra, Vice President Investor Relations | ||
Robert Decker, Controller Officer | ||
Ashley McEvoy, Executive Vice President - Worldwide Chairman, Medical Devices | ||
Ronald Williams, Independent Director | ||
Kathryn Wengel, Executive Vice President Chief Global Supply Chain Officer | ||
James Swanson, Ex Officer | ||
D Davis, Independent Director | ||
Hubert Joly, Independent Director | ||
Anne Mulcahy, Lead Independent Director | ||
Joseph Wolk, Chief Financial Officer, Executive Vice President | ||
Thibaut Mongon, Executive Vice President Worldwide Chairman, Consumer | ||
Jessica Moore, VP Relations | ||
Ian Davis, Independent Director | ||
Paulus Stoffels, Worldwide Chairman of Pharmaceuticals, Chief Scientific Officer and Member of Executive Committee | ||
Mark McClellan, Independent Director | ||
Charles Prince, Independent Director | ||
Eugene Washington, Independent Director | ||
Elizabeth Forminard, Exec Counsel | ||
Dominic Caruso, CFO, VP of Fin. and Member of Executive Committee | ||
Peter Fasolo, Chief Human Resource Officer, Executive Vice President | ||
Susan Lindquist, Independent Director | ||
Mark Weinberger, Independent Director |
Johnson Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Johnson Johnson a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.24 | |||
Return On Asset | 0.0881 | |||
Profit Margin | 0.19 % | |||
Operating Margin | 0.27 % | |||
Current Valuation | 9.15 T | |||
Shares Outstanding | 2.61 B | |||
Shares Owned By Insiders | 0.09 % | |||
Shares Owned By Institutions | 70.93 % | |||
Price To Earning | 28.71 X | |||
Price To Book | 6.26 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Johnson Johnson. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Johnson Stock please use our How to Invest in Johnson Johnson guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Complementary Tools for Johnson Stock analysis
When running Johnson Johnson's price analysis, check to measure Johnson Johnson's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Johnson Johnson is operating at the current time. Most of Johnson Johnson's value examination focuses on studying past and present price action to predict the probability of Johnson Johnson's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Johnson Johnson's price. Additionally, you may evaluate how the addition of Johnson Johnson to your portfolios can decrease your overall portfolio volatility.
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |